Back to top

biotechs: Archive

Zacks Equity Research

BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook

BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.

ALNYPositive Net Change BMYNegative Net Change PFENegative Net Change BMRNPositive Net Change

Zacks Equity Research

AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.

SNYNegative Net Change AZNPositive Net Change MRKNegative Net Change AMGNNegative Net Change

Debanjana Dey

Zacks Initiates Coverage of bioAffinity With Neutral Recommendation

Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challenges.

BIAFPositive Net Change

Zacks Equity Research

RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?

Rezolute rides on robust clinical development activity for lead candidate ersodetug (RZ358) for treating hypoglycemia caused by hyperinsulinism.

BMRNPositive Net Change RZLTNegative Net Change CSTLNegative Net Change HRMYNegative Net Change

Zacks Equity Research

RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study

Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.

ALNYPositive Net Change BMRNPositive Net Change RAREPositive Net Change CSTLNegative Net Change

Zacks Equity Research

GHRS Stock Rallies 55% in a Week: Here's What You Should Know

GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.

ALNYPositive Net Change BMRNPositive Net Change CSTLNegative Net Change GHRSNegative Net Change

Zacks Equity Research

Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.

ALNYPositive Net Change NVSNegative Net Change PTCTNegative Net Change

Zacks Equity Research

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

BMRNPositive Net Change VKTXNegative Net Change CSTLNegative Net Change ERASNegative Net Change

Kinjel Shah

5 Promising Price-to-Book Value Stocks to Buy in February

The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, USNA, GBX, KT and ENS are some such stocks.

KTPositive Net Change GMPositive Net Change GBXNegative Net Change ENSPositive Net Change USNANegative Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.

AMGNNegative Net Change VRTXNegative Net Change MRNANegative Net Change SRPTNegative Net Change CRSPNegative Net Change

Zacks Equity Research

Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval

REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.

REGNPositive Net Change BIIBNegative Net Change AMGNNegative Net Change AXSMNegative Net Change VRTXNegative Net Change

Zacks Equity Research

NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes and Obesity care products.

ALNYPositive Net Change NVOPositive Net Change LLYPositive Net Change CSTLNegative Net Change

Kanishka Das

Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).

VRTXNegative Net Change MRNANegative Net Change CRSPNegative Net Change

Zacks Equity Research

GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

SNYNegative Net Change GSKNegative Net Change JNJNegative Net Change VIRPositive Net Change

Zacks Equity Research

Company News for Feb 5, 2025

Companies In The News Are: RACE, REGN, MPLX, WEC.

REGNPositive Net Change WECNegative Net Change MPLXNegative Net Change RACENegative Net Change

Zacks Equity Research

Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,

REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change

Zacks Equity Research

Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know

INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.

NVSNegative Net Change INCYNegative Net Change EXELPositive Net Change MIRMNegative Net Change

Zacks Equity Research

Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 View

MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has affected its 2025 sales forecast.

AZNPositive Net Change MRKNegative Net Change CSTLNegative Net Change ERASNegative Net Change

Zacks Equity Research

PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS

Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.

ALNYPositive Net Change PFENegative Net Change LLYPositive Net Change CSTLNegative Net Change

Zacks Equity Research

BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.

ALNYPositive Net Change BMYNegative Net Change BMRNPositive Net Change EXELPositive Net Change

Zacks Equity Research

Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?

Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.

BMYNegative Net Change PFENegative Net Change MRKNegative Net Change LLYPositive Net Change AMGNNegative Net Change

Ekta Bagri

Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?

BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock. We recommend investors to wait for better entry levels.

BMYNegative Net Change PFENegative Net Change TSVTNegative Net Change

Ahan Chakraborty

Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.

NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change VKTXNegative Net Change

Zacks Equity Research

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.

BIIBNegative Net Change LLYPositive Net Change PRTANegative Net Change CSTLNegative Net Change

Sundeep Ganoria

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

AMGNNegative Net Change VRTXNegative Net Change MRNANegative Net Change SRPTNegative Net Change CRSPNegative Net Change